Tags

Type your tag names separated by a space and hit enter

Listeria infection after treatment with alemtuzumab: a case report and literature review. Would antibiotic prophylaxis be considered?
Infez Med. 2020 Jun 01; 28(2):258-262.IM

Abstract

Few cases of complicated infections with Listeria monocytogenes (LM) have been reported to date in patients with multiple sclerosis (MS) treated with alemtuzumab. Primary prevention strategies may be suggested in such patients to avoid infections. However, these may be ineffective because patients may already be carriers of LM. We report herein a case of bloodstream infection due to LM in a 25-year-old woman with MS treated with alemtuzumab. We searched the UMC/WHO Vigibase system for all reported cases of LM in patients treated with alemtuzumab and found 29 cases overall up to 21 July 2019. We also performed a literature review of MS cases with LM on alemtuzumab, in order to evaluate epidemiology, clinical characteristics, and outcome of this complication. Since the published cases (N=8) were mainly reported in recent years but more cases were found in the UMC/WHO Vigibase system (although not necessarily in patients with MS), we hypothesize that this complication is more frequent than currently believed and may become even more important in the future. Therefore, it is worth reaching a consensus on appropriate algorithms to stratify individuals by risk so as to implement targeted prevention strategies (whether primary or secondary).

Authors+Show Affiliations

Department of Medical and Surgical Sciences, Infectious and Tropical Diseases Unit, "Magna Graecia" University, Catanzaro, Italy; Research and Development Department, Chelsea and Westminster Hospital Foundation Trust, London, United Kingdom.Institute of Neurology, "Magna Graecia" University, Catanzaro, Italy.Department of Medical and Surgical Sciences, Infectious and Tropical Diseases Unit, "Magna Graecia" University, Catanzaro, Italy.Department of Medical and Surgical Sciences, Infectious and Tropical Diseases Unit, "Magna Graecia" University, Catanzaro, Italy.Institute of Neurology, "Magna Graecia" University, Catanzaro, Italy.Department of Health Sciences, Clinical Microbiology Unit, "Magna Graecia" University, Catanzaro, Italy.Department of Medical and Surgical Sciences, Infectious and Tropical Diseases Unit, "Magna Graecia" University, Catanzaro, Italy.Department of Medical and Surgical Sciences, Infectious and Tropical Diseases Unit, "Magna Graecia" University, Catanzaro, Italy.Department of Health Sciences, Clinical Microbiology Unit, "Magna Graecia" University, Catanzaro, Italy.Department of Health Sciences, Clinical Microbiology Unit, "Magna Graecia" University, Catanzaro, Italy.Department of Health Sciences, Clinical Microbiology Unit, "Magna Graecia" University, Catanzaro, Italy.Institute of Neurology, "Magna Graecia" University, Catanzaro, Italy.Department of Medical and Surgical Sciences, Infectious and Tropical Diseases Unit, "Magna Graecia" University, Catanzaro, Italy.Department of Medical and Surgical Sciences, Infectious and Tropical Diseases Unit, "Magna Graecia" University, Catanzaro, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32487792

Citation

Mazzitelli, Maria, et al. "Listeria Infection After Treatment With Alemtuzumab: a Case Report and Literature Review. Would Antibiotic Prophylaxis Be Considered?" Le Infezioni in Medicina, vol. 28, no. 2, 2020, pp. 258-262.
Mazzitelli M, Barone S, Greco G, et al. Listeria infection after treatment with alemtuzumab: a case report and literature review. Would antibiotic prophylaxis be considered? Infez Med. 2020;28(2):258-262.
Mazzitelli, M., Barone, S., Greco, G., Serapide, F., Valentino, P., Giancotti, A., Costa, C., Pisani, V., Quirino, A., Liberto, M. C., Matera, G., Gambardella, A., Trecarichi, E. M., & Torti, C. (2020). Listeria infection after treatment with alemtuzumab: a case report and literature review. Would antibiotic prophylaxis be considered? Le Infezioni in Medicina, 28(2), 258-262.
Mazzitelli M, et al. Listeria Infection After Treatment With Alemtuzumab: a Case Report and Literature Review. Would Antibiotic Prophylaxis Be Considered. Infez Med. 2020 Jun 1;28(2):258-262. PubMed PMID: 32487792.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Listeria infection after treatment with alemtuzumab: a case report and literature review. Would antibiotic prophylaxis be considered? AU - Mazzitelli,Maria, AU - Barone,Stefania, AU - Greco,Giuseppe, AU - Serapide,Francesca, AU - Valentino,Paola, AU - Giancotti,Alda, AU - Costa,Chiara, AU - Pisani,Vincenzo, AU - Quirino,Angela, AU - Liberto,Maria Carla, AU - Matera,Giovanni, AU - Gambardella,Antonio, AU - Trecarichi,Enrico Maria, AU - Torti,Carlo, PY - 2020/6/4/entrez SP - 258 EP - 262 JF - Le infezioni in medicina JO - Infez Med VL - 28 IS - 2 N2 - Few cases of complicated infections with Listeria monocytogenes (LM) have been reported to date in patients with multiple sclerosis (MS) treated with alemtuzumab. Primary prevention strategies may be suggested in such patients to avoid infections. However, these may be ineffective because patients may already be carriers of LM. We report herein a case of bloodstream infection due to LM in a 25-year-old woman with MS treated with alemtuzumab. We searched the UMC/WHO Vigibase system for all reported cases of LM in patients treated with alemtuzumab and found 29 cases overall up to 21 July 2019. We also performed a literature review of MS cases with LM on alemtuzumab, in order to evaluate epidemiology, clinical characteristics, and outcome of this complication. Since the published cases (N=8) were mainly reported in recent years but more cases were found in the UMC/WHO Vigibase system (although not necessarily in patients with MS), we hypothesize that this complication is more frequent than currently believed and may become even more important in the future. Therefore, it is worth reaching a consensus on appropriate algorithms to stratify individuals by risk so as to implement targeted prevention strategies (whether primary or secondary). SN - 1124-9390 UR - https://www.unboundmedicine.com/medline/citation/32487792/Listeria_infection_after_treatment_with_alemtuzumab:_a_case_report_and_literature_review._Would_antibiotic_prophylaxis_be_considered L2 - https://www.infezmed.it/index.php/article?Anno=2020&numero=2&ArticoloDaVisualizzare=Vol_28_2_2020_258 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.